

Novel trends in endocrine disruptor testing: the H295R Steroidogenesis Assay for identification of inducers and inhibitors of hormone production

Markus Hecker · John P. Giesy

Published online: 24 October 2007
© Springer-Verlag 2007

Introduction

Over the past two decades, there has been increasing concern about the possible impacts of exposure to chemicals in the environment on endocrine and reproductive systems in humans and wildlife [1]. To address these concerns, national and international programs have been initiated to develop new guidelines for the screening and testing of potential endocrine-disrupting chemicals (EDCs) in vertebrates [2, 3]. The focus of these multi-tiered programs was to develop *in vitro* and *in vivo* assays to identify and classify chemicals relative to their potential interaction with endocrine systems (Tier 1), and then to develop concentration–response relationships in animal models (Tier 2) [2]. In this article we will focus on a new *in vitro* bioassay to test for the potential of chemicals to interfere with steroid hormone production. This assay is currently being developed as part of Tier 1 of the USEPA Endocrine Disruptor Screening Program and an Organization for Economic Cooperation and Development (OECD) test method validation program [4].

Most of the efforts to develop screening assays for endocrine disruptor testing have been focused on the development and validation of *in vitro* hormone receptor-binding assays including the estrogen receptor (ER) and the androgen receptor (AR) [5–7]. However, it should be acknowledged that there are a number of non-receptor-mediated processes that may also alter endocrine function [8]. These include chemical-induced modulation of the enzymes involved in the production, transformation, or elimination of steroid hormones, which can result in alterations of the absolute and relative concentrations of hormones in blood and tissues [9]. Often, these non-receptor-mediated effects are caused indirectly via alterations of common signal-transduction pathways [10], or through direct competitive or non-competitive inhibition of the enzyme.

Steroid sex hormones are key factors involved in the regulation of reproduction in vertebrates and are also involved in numerous other processes that are related to development and growth [11]. Thus, chemicals that can disrupt the production of sex steroids may be directly linked to adverse outcomes for these processes. To address the potential issues of exposure to chemicals that may result in the disturbance of sex steroid homeostasis, therefore, several *in vivo* test systems have been evaluated. These tests include the pubertal male and female rat assays, the fish reproductive screen, and the frog thyroid assay. Furthermore, several *in vitro* screening methods have been developed including the microsomal aromatase assay and a rodent minced-testis assay [2]. Some of these assays such as the rodent minced-testis have shown some promise regarding their potential to identify effects on androgen production. However, a number of questions have been raised about the utility of rodent-based explant assays in that they were found to yield high rates of false positive or

M. Hecker (✉)
Entrix, Inc., Toxicology Centre, University of Saskatchewan,
44 Campus Drive,
Saskatoon SK S7N 5B3, Canada
e-mail: mhecker@entrinx.com

M. Hecker · J. P. Giesy
Department of Veterinary Biomedical Sciences
and Toxicology Centre, University of Saskatchewan,
Saskatoon, SK S7N 5B3, Canada

J. P. Giesy
Department of Biology and Chemistry,
City University of Hong Kong,
Hong Kong, SAR, China

negative responses [12]. Also, in testis explant assays it is not possible to discriminate between cytotoxicity of hormone-producing cells and other cell types. Finally, there has been increasing criticism regarding the use of animals in screening type assays. As a result, there has been a need for less variable and more reliable in vitro test systems as alternatives to tissue explant assays that allow testing for the effects of chemicals on hormone production.

The H295R Steroidogenesis Assay

One cell line that has been shown to be a useful in vitro model for steroidogenic pathways and processes is the human H295R adrenocarcinoma cell line [8, 13]. The H295R cell line expresses genes that encode for all the key enzymes for steroidogenesis [10, 14] (Fig. 1). This is a unique property, because in vivo expression of these genes is tissue and developmental stage-specific with no one tissue or developmental stage expressing all of the genes involved in steroidogenesis. H295R cells have physiological characteristics of zonally undifferentiated human fetal adrenal cells [14]. The cells represent a unique in vitro system in that they have the ability to produce the steroid hormones found in the adult adrenal cortex and the gonads, allowing testing for effects on both corticosteroid synthesis and the production of sex steroid hormones such as androgens and estrogens. There are several additional advantages to the use of the H295R cell line. Its advantage over tissue-based assays is that it enables assessment of the potential impact of a chemical on cell viability and/or cytotoxicity. This is an important feature as it enables discrimination between effects due to cytotoxicity or to direct interaction with steroidogenic pathways, which is not possible in tissue explants that consist of multiple cell types. In addition, the NCI-H295R cells are commercially available from the American Type Culture Collections (ATCC CRL-2128; ATCC, Manassas, VA, USA). Thus,

these cells are available to everybody and no costly permissions are required as is the case for many other cell systems such as the CALUX assay.

Based on the promising results obtained during initial studies researching the potential of the H295R cells to detect effects of chemicals on steroidogenesis including the production of testosterone, estradiol, or progestins [8], a standardized H295R Steroidogenesis Assay protocol was developed. The protocol is currently being tested in conjunction with the OECD in an international laboratory setting under the participation of seven independent laboratories [4]. In brief, the assay is performed under standard cell-culture conditions in 24-well culture plates (Fig. 2). After an acclimation period of 24 h, cells are exposed for 48 h to multiple concentrations of the test chemical in triplicate. In parallel, a plate with known inhibitors and inducers of hormone production is run as a quality control (QC). At the end of the exposure period, the medium is removed from each well and hormones are extracted using diethyl ether. Cell viability in each well is analyzed immediately after removal of the medium. Concentrations of hormones in the medium can be measured using commercially available hormone-detection kits, again making the assay accessible to most laboratories.

An initial inter-laboratory pre-validation study demonstrated that the H295R Steroidogenesis protocol is highly reproducible, transferable, and is a sensitive, reliable, economic, and precise method to test for chemical effects on the production of T and E2 [4]. Comparison of changes in hormone production by H295R cells that were exposed to three model compounds with known modes of interaction with the steroidogenic pathway, forskolin, prochloraz and fadrozole, revealed a high degree of reproducibility of the tested protocol among five independent laboratories (Fig. 3). However, H295R cells appear to maintain some flexibility concerning their hormone-producing capacities, which is likely to be due to the undifferentiated characteristics of the cells [14]. Interestingly, both the direction and

Fig. 1 Steroidogenic pathway in H295R cells. Enzymes are in *italics*, hormones are in **bold**, and *arrows* indicate the direction of synthesis. *Gray background* indicates corticosteroid pathways/products. Sex steroid pathways/products are *circled*. CYP = cytochrome P450; HSD = hydroxysteroid dehydrogenase





Fig. 2 H295R Steroidogenesis Assay to measure effects of chemicals on production of testosterone and estradiol




1. Begin H295R cell culture using an original ATCC batch
2. Culture cells for ≥ 5 passages (split cells when $\sim 90\%$ confluent)
3. Seed at a density of 300,000 cells/mL into 24 well plates, and incubate at 37°C and 5% CO₂ for 24h
4. Replace medium and dose cells
5. Incubate at 37°C and 5% CO₂ for 48h
6. Remove medium from cells and extract with ether
7. Conduct cell viability assay immediately after removal of medium
8. Measure hormone concentrations in medium extract

extent of the changes in hormone production with cell age are predictable and reproducible among different laboratories (Hecker, personal communication). Furthermore, it was demonstrated that, despite the differences in absolute concentrations of hormones as a function of cell age, the

relative response of the H295R cells in response to the exposure with chemicals remained constant [8]. To overcome some of the uncertainties resulting from this variable nature of the cells, efforts are currently underway to standardize the cell-culture protocols in preparation for

Fig. 3 Comparison of changes in testosterone (*T*) (a, c) and estradiol (*E2*) (b, d) production by H295R cells among five independent laboratories (*Lab 1–Lab 5*). Data are expressed as percentages of the minimum or maximum hormone concentrations measured across all doses (maximum suppression = -100% ; maximum induction = 100%) observed after exposure to forskolin (a, b) and prochloraz (c, d) for 48 h. Data represents the mean of three independent exposure experiments. *SC* = solvent control (0.01% v/v DMSO)



exposure studies. In addition, different data-evaluation techniques that allow normalization of the data to correct for differences due to cell age are employed. In this context, both expression of data as changes relative to the controls and as percent maximum efficacy are very promising.

While the undifferentiated nature of the cells and the changes in hormone production with cell age may, in some cases, result in an increased variability of some of the results, it seems to be advantageous for the utilization of this *in vitro* system as a predictive tool for effects at higher levels of organization such as tissues or whole organisms. Most of the currently established *in vitro* systems used to identify potential EDCs, such as the hormone receptor binding assays, are relatively artificial systems that only allow testing for very specific modes of action. The benefit of such specific test systems is that they allow pinpointing the mode of action of a chemical. This is, however, typically at the cost of a reduced predictive power regarding any possible *in vivo* effects as these systems often lack *in vivo* features such as metabolic enzymes or feedback loops. In contrast, the H295R cells appear to have maintained many of the characteristics of the tissue they were derived from, the adrenal cortex, and comparison studies with higher organizational level tests such as tissue explants have demonstrated good predictive power for model compounds that were previously shown to interact with steroidogenesis [15]. Beyond measurement of hormone production, the H295R cell bioassay can be used to evaluate effects of chemicals on gene expression and the enzymatic activities of steroidogenic genes [8]. Understanding of interactions between these different endpoints is essential for the development of models that predict likely shifts in the flux of various steroid precursors that would result from inhibition or induction of one or more enzymes in the synthetic pathway (Fig. 1), and that ultimately can help define mechanisms of actions for poorly characterized chemicals in support of predictive toxicological risk assessments [15].

Outlook

While H295R cells have been successfully utilized in studies of the potential effects of chemicals on various aspects of steroidogenesis including gene expression [13], catalytic enzyme activities [16], and steroid hormones [8], relatively little is known about their basic properties including the stability of steroidogenic processes, metabolic capacities, and steroid biotransformation. Especially when considering the “evolving” nature of the H295R cells, understanding of these properties appears to be of great importance not only for the immediate interpretation of results but also with regard to the predictability of these for higher levels of organization. A series of studies have

recently been initiated, therefore, to better characterize the H295R cell line in terms of their metabolizing capacities, stability of hormone production over time, and steroid biotransformation.

Despite the remaining uncertainties regarding the predictive nature of results obtained with the H295R Steroidogenesis Assay for higher levels of organization, it was demonstrated that this assay is a powerful and reliable screening tool to evaluate the effects of chemicals on steroidogenesis, specifically the production of the sex steroid hormones T and E2. Due to its characteristics the H295R Steroidogenesis Assay is currently being evaluated by both the US-EPA and OECD as a Tier 1 screening assay for the effects of chemicals on the production of T and E2. Specifically, the assay is currently evaluated for use in EPA’s mandatory Endocrine Disruptor-Screening Program to be implemented in 2008.

Acknowledgements We thank the OECD Validation and Management Group for Non-Animal Testing (VMG NA), the OECD secretariat, and the US-EPA, ORD Service Center/NHEERL for their support, encouragement, and guidance. Special thanks go to Mr Gary Timm for many helpful discussions and manuscript review.

References

1. Kavlock RJ, Daston GP, De Rosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster M, Mac MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T, Tilson HA (1996) *Environ Health Perspect* 104:715–740
2. EDSTAC (1988): Endocrine disruptor screening and testing advisory committee final report, 1998. Internet access at URL: <http://www.epa.gov/opptintr/opptendo/finalrpt.htm>, US Environmental Protection Agency
3. OECD (1998) Report of the First Meeting of the OECD Endocrine Disruptor Testing and Assessment (EDTA) Working Group. OECD Paris
4. Hecker M, Hollert H, Cooper R, Vinggaard A-M, Akahori Y, Murphy M, Nellesmann C, Higley E, Newsted J, Wu R, Lam P, Laskey J, Buckalew A, Grund S, Nakai M, Timm G, Giesy J (2007) *Environ Sci Pollut Res* 14(Special Issue 1):23–30
5. Villeneuve DL, Blankenship AL, Giesy JP (1998) Estrogen receptors—environmental xenobiotics. In: Denison MS, Helderich WG (eds) *Toxicant–receptor interactions and modulation of gene expression*. Lippincott–Raven, Philadelphia
6. Wilson VS, Bobseine K, Lambright CR, Gray LE (2002) *Toxicol Sci* 66:69–81
7. Wilson VS, Bobseine K, Gray LE (2004) *Toxicol Sci* 81:69–77
8. Hecker M, Newsted JL, Murphy MB, Higley EB, Jones PD, Wu R, Giesy JP (2006) *Toxicol Appl Pharmacol* 217:114–124
9. Ohno S, Shinoda S, Toyoshima S, Nakazawa H, Makino T, Nakajin S (2002) *J Steroid Biochem Mol Biol* 80:355–363
10. Rainey EW, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R, Mason JI (1993) *J Clin Endocrinol Metab* 77:731–737
11. Norris DO (1997) *Vertebrate endocrinology*, 3rd edn. Academic Press, San Diego, CA, USA
12. Powlin SS, Cook JC, Novak S, O’Connor JC (1998) *Toxicol Sci* 46:61–74

13. Hilscherova K, Jones PD, Gracia T, Newsted JL, Zhang X, Sanderson JT, Yu RMK, Wu RSS, Giesy JP (2004) *Toxicol Sci* 81:78–89
14. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV (1990) *Cancer Res* 50:5488–5496
15. Villeneuve DL, Ankley GT, Makynen EA, Blake LS, Greene KJ, Higley EB, Giesy JP, Hecker M (2007) *Ecotoxicol Environ Saf* 68:20–32
16. Breen MS, Villeneuve DL, Ankley GT, Connolly RB (2007) *Biomedical Engineering Society (BMES) Annual Meeting*, Chicago, IL, October. 2006